Document is current
Any future updates will be listed below
-
Authors
Robles-Plaza, Mireya https://orcid.org/0009-0003-7340-2721
Gómez-Peralta, Fernando https://orcid.org/0000-0003-0106-0091
Bellido, Virginia https://orcid.org/0000-0002-8384-043X
Ampudia-Blasco, Francisco Javier https://orcid.org/0000-0003-0221-0901
Carretero-Gómez, Juana https://orcid.org/0000-0002-7754-6090
Cebrián-Cuenca, Ana María https://orcid.org/0000-0003-3710-6370
de la Cuadra-Grande, Alberto https://orcid.org/0000-0002-2501-3049
Mezquita-Raya, Pedro https://orcid.org/0000-0002-1536-8364
-
Funding
Funding for this research was provided by:
Abbott Diabetes Care
- License Information
-
More Information
Article History
Received: 17 September 2025
Accepted: 16 October 2025
First Online: 7 November 2025
Declarations
:
: Mireya Robles-Plaza and Alberto de la Cuadra-Grande are employees of PORIB, a consultant company specializing in economic evaluation of health care interventions and outcomes research, which received fees for providing methodological support to this project. Fernando Gómez-Peralta has taken part in advisory panels for Abbott, Insulcloud S.L., Sanofi and Novo Nordisk; has received research support from Sanofi, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals and Lilly; and has acted as a speaker for Abbott, Sanofi, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co. and Lilly. Virginia Bellido has served as a consultant/advisor for Abbott Diabetes Care, AstraZeneca, Eli Lilly, Merck, Novo Nordisk, and Sanofi and as a speaker for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi and has received grant support from Abbott Diabetes Care, Eli Lilly, Novo Nordisk and Sanofi. Francisco Javier Ampudia-Blasco has served as a consultant/advisor for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, LifeScan, MannKind Co., Medtronic, Menarini, Merck, Novartis, Novo Nordisk, and Sanofi and as a speaker for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, LifeScan, Eli Lilly, Madaus, Medtronic, Menarini, Merck, Novartis, Novo Nordisk, and Sanofi and has received grant support from Novo Nordisk and Sanofi. Juana Carretero Gómez reported receiving consulting fees and speaking from AstraZeneca, Boehringer Ingelheim, Lilly, Abbot Diabetes Care and Novo Nordisk. Ana María Cebrián-Cuenca has served as a consultant/advisor for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini, Merck, Novo Nordisk, and Sanofi and as a speaker for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Menarini, Merck, Novartis, Novo Nordisk, and Sanofi and has received grant support from Merck, Novo Nordisk and Sanofi. Pedro Mezquita-Raya has served as a consultant/advisor on scientific boards for Abbott, AstraZeneca, FAES and Novo Nordisk; as a speaker for AstraZeneca, Eli Lilly, FAES, Fresenius and Novo Nordisk; and in research activities for Eli Lilly & Company and Novo Nordisk. None of the authors received fees for being listed in this manuscript’s authorship.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
